Core Insights - Conduit Pharmaceuticals is integrating advanced AI and cybernetics to enhance drug development processes, aiming to streamline operations and improve efficiency [1][3] - The company has completed initial milestones in collaboration with Sarborg Limited, focusing on AI-driven processes tailored to Conduit's portfolio [2][3] - Conduit aims to lead in the application of advanced technology in the pharmaceutical sector, promising faster and more cost-effective drug development [3] Company Overview - Conduit Pharmaceuticals is a clinical-stage life science company that develops Phase 2-ready assets and employs an AI-driven approach to drug development [4] - The company is led by experienced pharmaceutical executives, including Dr. David Tapolczay and Dr. Freda Lewis-Hall, and seeks to exit through third-party licensing deals after successful clinical trials [4]

Core Viewpoint - Conduit Pharmaceuticals Inc. has announced a 1-for-100 reverse stock split to comply with Nasdaq's minimum bid price requirement and enhance the stock's marketability [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect on January 24, 2025, at 5:00 PM Eastern Time, with trading on a reverse-adjusted basis starting January 27, 2025 [2]. - Every 100 shares of common stock will be combined into one share, resulting in approximately 1.5 million outstanding shares post-split [3][4]. - The par value per share remains unchanged at $0.0001, and adjustments will be made to equity awards and convertible securities accordingly [3]. Group 2: Trading and Administrative Aspects - The common stock will continue to trade under the ticker symbol "CDT" with a new CUSIP number of 20678X205 after the reverse stock split [4]. - No fractional shares will be issued; stockholders entitled to fractional shares will receive a proportional cash payment [4]. - VStock Transfer, LLC will act as the exchange agent, and registered stockholders will not need to take action to receive post-split shares [5]. Group 3: Company Overview - Conduit Pharmaceuticals is a clinical stage, disease-agnostic life science company focused on efficient compound development, acquiring and funding Phase 2-ready assets [7]. - The company aims to exit through third-party license deals following successful clinical trials, differing from traditional pharma/biotech models [7].

Core Insights - Conduit Pharmaceuticals has entered into a strategic services agreement with Agility Life Sciences to develop new solid oral-dosage form products for its autoimmune pipeline, aimed at future clinical trials [1][2] Group 1: Company Overview - Conduit Pharmaceuticals is a multi-asset, clinical stage, disease-agnostic life science company focused on acquiring and funding Phase 2-ready assets, seeking exits through third-party licensing deals after successful clinical trials [5] - Agility Life Sciences is an award-winning formulation development CDMO that specializes in creating smart formulations to enhance the probability of success in pre-clinical studies [4] Group 2: Strategic Collaboration - The collaboration with Agility will leverage Conduit's proprietary solid forms, protected by newly established composition-of-matter intellectual property, to develop enhanced oral dosage forms tailored to patient preferences and disease-specific needs [2][3] - Conduit’s pipeline includes candidates with clinically tested oral formulations, allowing for efficient advancement into Phase 2 trials using existing data packages [3] Group 3: Market Positioning - The dual-track approach of developing enhanced proprietary oral dosage formulations while conducting ongoing clinical trials is intended to strengthen market protection, enhance market value, and optimize positioning for future licensing opportunities [3]

Core Insights - Conduit Pharmaceuticals has partnered with SARBORG Limited to utilize artificial intelligence and cybernetics for enhancing drug development processes, including drug repurposing, discovery, and clinical trial monitoring [1][2][3] Group 1: Partnership Details - The agreement with SARBORG aims to address challenges in the pharmaceutical sector by reducing human error in decision-making processes related to clinical development and asset identification [3][4] - Conduit will gain access to advanced predictive models and dashboards, which will facilitate the evaluation of drug candidates and streamline clinical trials [4][5] Group 2: Strategic Advantages - By integrating SARBORG's AI and cybernetics technology, Conduit aims to enhance efficiency, lower costs, and accelerate timelines in drug development [3][6] - The partnership is expected to provide Conduit with a strategic advantage, allowing for quicker and more accurate identification of opportunities in the market [7] Group 3: Long-term Vision - Conduit retains a perpetual, non-exclusive, royalty-free right to use any technology developed by SARBORG, ensuring ongoing support and innovation in areas such as intellectual property creation and regulatory strategy [5][6] - The collaboration reinforces Conduit's commitment to leveraging AI-driven solutions to maintain a competitive edge in the pharmaceutical industry [6]

Core Insights - Conduit Pharmaceuticals has received approval from the Japan Patent Office for a composition of matter patent for its lead asset, AZD1656, which targets autoimmune disorders [1][2] - This patent approval follows a similar grant in Australia, indicating the company's ongoing efforts to protect its intellectual property and enhance out-licensing opportunities [1][2] Company Overview - Conduit Pharmaceuticals operates with a unique business model aimed at addressing unmet medical needs by enhancing the intellectual property of its assets through advanced solid-form technology [3] - The company holds exclusive licenses with AstraZeneca for AZD1656, AZD5658, and AZD5904, and has additional cocrystal assets, including CDT1656, which expands its innovative portfolio [4] - The primary indications targeted by Conduit are Lupus and ANCA Vasculitis [4] Leadership - The company is led by a team of experienced pharmaceutical executives, including CEO Dr. David Tapolczay and Chair Dr. Freda Lewis-Hall, both of whom have significant backgrounds in the industry [5]

Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30 years of experience in asset management, capital markets, and strategy development. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development, today an ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41245 CONDUIT PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) | --- | --- | --- | |------------- ...

Conduit Pharmaceuticals announces new addition to its autoimmune pipeline, underscored by composition of matter patent filing to strengthen its competitive position This new asset, CDT1656, combines AZD1656 with a second known-compound that has demonstrated immune-modulating effects across multiple autoimmune conditions, enhancing its therapeutic potentialThe addition of CDT1656 and the supporting composition of matter patent filing highlight Conduit’s commitment to building a robust asset portfolio, positi ...

SAN DIEGO and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced the restructuring of a portion of its financial obligations, enhancing its balance sheet and liquidity. The Company has restructured the $2.65 million loan note with Nirland Limited (“Nirland”) and secured $1.2 million in new promissory notes through separate agreements with third parties. Conduit entered into a $2.65 million loan note with Nirland on August 6, 202 ...

Group 1 - Conduit Pharmaceuticals (NASDAQ:CDT) stock experienced an increase following a shareholder update revealing that Nirland Limited holds a 14.8% stake in the company [1][2] - Nirland Limited's stake consists of 12.5 million shares and warrants for an additional 2 million shares, based on the company's outstanding shares of 98,004,699 [2] - The stake was acquired through a Senior Secured Promissory Note as part of Conduit Pharmaceuticals' merger agreement with Murphy Canyon Acquisition Corp [2] Group 2 - Following the news, CDT stock saw heavy trading with over 72 million shares changing hands, significantly higher than the daily average of about 10 million shares [3] - As of Wednesday morning, CDT stock rose by 11.7%, although it remains down 96.7% since the beginning of the year [3]